Collaboration Advances Genomic Instability Biomarker for Prostate Cancer

In prostate cancer, homologous recombination deficiency is emerging as an important prognostic and predictive biomarker. Measuring the chromosomal instability associated with this pathway may help guide precision oncology research and treatment development. Building on this potential, a new collaboration aims to advance a prostate cancer-specific genomic instability score for use in clinical trials and potential companion diagnostic development.

The prostate cancer-specific genomic instability score (PrGIS) technology is being advanced by Sophia Genetics (Rolle, Switzerland) and Myriad Genetics (Salt Lake City, UT, USA) in collaboration with AstraZeneca. PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in patients with prostate cancer. Myriad developed PrGIS to support homologous recombination deficiency as an actionable biomarker in prostate cancer.

The proprietary MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will generate the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, Sophia Genetics is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad’s PrGIS technology and is intended to expand patient access to PrGIS in global markets.

Sophia Genetics’ technology-agnostic, cloud-based platform supports local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. PrGIS is intended to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies. No performance metrics were reported.

Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period.

“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world. By pairing Myriad’s world-class biomarker innovation with Sophia Genetics’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most,” said Jess Lambe, VP & Managing Director of BioPharma Business Development, Sophia Genetics.

Related Links
Sophia Genetics
Myriad Genetics